Human papillomavirus vaccine - MediGene/Virionics

Drug Profile

Human papillomavirus vaccine - MediGene/Virionics

Alternative Names: Chimeric virus-like particle; CVLP-vaccine; HPV-16 L1-E7 chimeric VLP; PapViRx

Latest Information Update: 30 Aug 2010

Price : $50

At a glance

  • Originator MediGene AG
  • Developer MediGene AG; Virionics
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections; Vulvar intraepithelial neoplasia

Most Recent Events

  • 11 Mar 2008 Preclinical trials in Cervical intraepithelial neoplasia in USA (unspecified route)
  • 11 Mar 2008 Preclinical trials in Human papillomavirus infections in USA (unspecified route)
  • 04 Apr 2006 Preclinical trials in Cervical cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top